aTYR PHARMA INC
aTyr Pharma, Inc. (NASDAQ: ATYR) is a clinical-stage biotechnology company focused on developing novel biologic therapies for fibrosis and inflammation by leveraging evolutionary intelligence to translate tRNA synthetase biology into new treatments. The company's website is www.atyrpharma.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What aTYR PHARMA INC does
In the company’s own words
aTyr Pharma, Inc. (NASDAQ: ATYR) is a clinical-stage biotechnology company focused on developing novel biologic therapies for fibrosis and inflammation by leveraging evolutionary intelligence to translate tRNA synthetase biology into new treatments. The company's website is www.atyrpharma.com.
The company's lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders characterized by inflammation and fibrosis of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve aberrant inflammation without immune suppression and potentially prevent fibrosis progression. The FDA has granted efzofitimod orphan drug designations for sarcoidosis and systemic sclerosis, along with Fast Track designations for pulmonary sarcoidosis and systemic sclerosis-associated interstitial lung disease. In September 2025, aTyr announced top-line data from the EFZO-FIT Phase 3 clinical trial evaluating efzofitimod in patients with pulmonary sarcoidosis, which did not meet its primary endpoint but demonstrated clinical improvements across multiple secondary endpoints including quality of life measures and fatigue assessment scores.
Beyond efzofitimod, aTyr has developed a discovery platform leveraging tRNA synthetase biology to identify novel therapeutic intervention points. The company has advanced two additional tRNA synthetase-derived candidates into preclinical development: ATYR0101, a fusion protein targeting myofibroblasts for fibrotic diseases, and ATYR0750, a novel ligand to fibroblast growth factor receptor 4 for inflammation and fibrosis-related diseases.
aTyr maintains a collaboration with Kyorin Pharmaceutical Co., Ltd. for development and commercialization of efzofitimod in Japan. Under this agreement, which has generated twenty million dollars in upfront and milestone payments to date, aTyr is eligible to receive up to an additional one hundred fifty-five million dollars upon achievement of development, regulatory, and sales milestones, plus tiered royalties on net sales in Japan.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1339970
- SIC
- 2836
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns aTYR PHARMA INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · aTYR PHARMA INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do aTYR PHARMA INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of aTYR PHARMA INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in aTYR PHARMA INC's last four quarterly filings that the numbers alone won't show?”